Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2001

View Archived Issues

Maxim to conduct phase II trial of Ceplene in triple combination therapy for hepatitis C

Duke University initiates phase I telomerase immunotherapy trial for prostate cancer

Fatty acid-targeted taxane undergoing phase II testing for breast and prostate cancer

ISIS-3521-containing combinations effective, well tolerated in NSCLC according to phase I/II data

Novel apoptosis-inducing anticancer agent developed at NCI

FDA issues notice on use of doxycycline and penicillin G procaine in treatment of anthrax

CeNeS terminates opiate spray agreement with Bioglan

TBI-361, a new chemo- and radiosensitizing PARP inhibitor

Xolair BLA amendment will be submitted in the fourth quarter of 2002

ChemGenex investigates molecular targets of Ceflatonin

Year-end completion of recruitment expected in renal cell carcinoma trial of Neovastat

Completion of rolling BLA submission for Erbitux

Inhaled iseganan safe in cystic fibrosis patients

Next-generation oncolytic virus from Onyx selectively propagates in tumor cells

Favorable sixth phase III safety review of VaxGen's AIDS vaccine

Combination of GTI-2040 and capecitabine examined in renal cell carcinoma

New multidrug resistance modulator designed at Penn State

Neurocrine Biosciences highlights positive Q3 developments

Raf kinase inhibitor Bay-43-9006 advances through phase I trials without significant toxicity

Pharmacyclics offers update of products in advanced clinical trials

New agents for osteoporosis in the AxyS pipeline

Merck scientists identify peptidomimetic compounds for Alzheimer's disease

Preparation and use of 1,5-benzothiazepines that inhibit bile acid transport

Pyrimidinone-based GSK3beta inhibitors and uses described by Sanofi-Synthelabo

Dainippon synthesizes pyridonecarboxylic acid antibacterial agents

Kitastato team discovers FKI-0076, a naturally produced antifungal enhancer

SGLT2 inhibitors from Kissei useful for diabetes, obesity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...